Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST Blueprint Medicines announced today that the FDA and the EMA have [...]
SPAEN (Sarcoma Patients EuroNet) Presents Webinar Webinar "Novel therapy options in GIST: What's on the horizon?" was presented by Dr. Jonathan Trent, Professor of Medicine, Associate Director, Clinical Research Director, Sarcoma Medical Research Program Sylvester [...]
The Life Raft Group held a GIST Day of Learning (GDOL) in Portland, at Oregon Health & Science University (OHSU), on June 22nd, 2019. GDOLs are free, one-day programs that provide both education and [...]
A GIST DO IT Walk was held prior to GDOL Portland 2019 at OHSU on 6/22/2019. GDOL participants walk to raise awareness and funds for GIST education.
Presentación del Dr. Chris Corless, profesor de patología en la Universidad de Oregón. Habla desde experiencia como patólogo trabajando con los tumores del estroma gastrointestinal (GIST). Nos actualiza sobre diagnóstico, mutaciones, riesgos de recurrencia, resistencia [...]
Real World Evidence in Action video presented by Piga Fernández, LRG Global Relations Coordinator, and Executive Director of Fundación GIST Chile, at New Horizons 2019.
This is the photo gallery for the New Horizons GIST Conference for 2019 held in NJ and hosted by the Life Raft Group. This international meeting aims to unify the global GIST patient advocacy community with key opinion leaders and facilitate ways to increase survival worldwide.
These are some memorable photos from Salud con Datos 2019. On May 7th, representatives from Colombia, Chile, Mexico, and The Life Raft Group assembled for the annual Salud con Datos meeting in Wayne, NJ. [...]
On May 4, 2019, The Life Raft Group held its first GIST DO IT Walk in New Jersey, at Verona Park. Despite the drizzle, over 50 people were in attendance and over $18K was raised for #GISTresearch.
The INTRIGUE study is a Phase 3 clinical trial testing the investigational drug ripretinib (DCC-2618) for patients living with GIST that are no longer on imatinib due to progression or intolerance.
